4 www.lexpert.ca
Feature
LIFE SCIENCES are enjoying a renaissance. With the
rise of telehealth — related but not tied to the COVID-19
pandemic — and research and investment in diagnostics,
oncolog y and psychedelics, the IPO and M&A markets in
the sector are bright.
"Life sciences' time has come," says Vanessa Grant, a
partner in Norton Rose Fulbright LLP's Toronto office.
Grant says she has seen several cycles in the sector during
her 24 years in practice. Although there was always interest
in investing in the life sciences sector, she says, COVID-19
has "really shone a bright light on the life sciences sector, and
to the good."
Investors, government and companies realize the value and
viability of the sector, including in Canada. A renewed interest
HEALTH SCIENCES
ARE IN THE PINK
INVESTORS, GOVERNMENT AND
COMPANIES ARE REALIZING THE
VALUE AND VIABILITY OF THE
LIFE SCIENCES SECTOR,
INCLUDING IN CANADA,
AND NOT ONLY DURING THE
COVID-19 PANDEMIC, WRITES
ELIZABETH RAYMER
"It's been a
phenomenal
year in 2020,
and we certainly
expect the same
for 2021."
Vanessa Grant
NORTON ROSE
FULBRIGHT LLP
